Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile

• Verfasst von: Neben, Kai [VerfasserIn]
• Verfasst von: Giesecke, Christian [VerfasserIn]
• Verfasst von: Schweizer, Silja [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Krämer, Alwin [VerfasserIn]
• Titel: Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile
• Verf.angabe: Kai Neben, Christian Giesecke, Silja Schweizer, Anthony D. Ho, Alwin Krämer
• E-Jahr: 2003
• Jahr: [1 January 2003]
• Umfang: 3 S.
• Fussnoten: Prepublished online as Blood first edition paper, June 28, 2002 ; Gesehen am 10.12.2021
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2003
• Band/Heft Quelle: 101(2003), 1 vom: Jan., Seite 289-291
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood-2002-04-1188
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1780941943

Abstract

Genetic instability is a common feature in acute myeloid leukemia (AML). Centrosome aberrations have been described as a possible cause of aneuploidy in many human tumors. To investigate whether centrosome aberrations correlate with cytogenetic findings in AML, we examined a set of 51 AML samples by using a centrosome-specific antibody to pericentrin. All 51 AML samples analyzed displayed numerical and structural centrosome aberrations (36.0% ± 16.6%) as compared with peripheral blood mononuclear cells from 21 healthy volunteers (5.2% ± 2.0%;P< .0001). In comparison to AML samples with normal chromosome count, the extent of numerical and structural centrosome aberrations was higher in samples with numerical chromosome changes (50.5% ± 14.2% versus 34.3% ± 12.2%;P< .0001). When the frequency of centrosome aberrations was analyzed within cytogenetically defined risk groups, we found a correlation of the extent of centrosome abnormalities to all 3 risk groups (P= .0015), defined as favorable (22.5% ± 7.3%), intermediate (35.3% ± 13.1%), and adverse (50.3% ± 15.6%). These results indicate that centrosome defects may contribute to the acquisition of chromosome aberrations and thereby to the prognosis in AML.